APDA-Funded Research Identifies a Genetic Mutation That May Protect Against Parkinson’s-Related Protein Buildup
APDA-funded research at Oregon Health & Science University (OHSU) has identified a rare genetic mutation that may help protect the brain from the buildup and spread of proteins associated with Parkinson’s disease (PD) and dementia with Lewy bodies.
The findings, published in Cell Reports in November 2026, are still at an early stage and are based on studies in mice. However, they raise an intriguing possibility: Scientists may eventually be able to use what they learn from this naturally occurring genetic mutation to develop new treatments aimed at slowing or preventing some of the underlying processes involved in these diseases.

The research focused on a rare version of the apolipoprotein E (APOE) gene called the Christchurch mutation. APOE is best known for its connection to Alzheimer’s disease, but it also influences the risk of dementia in people with PD and dementia with Lewy bodies.
The lead author of the study was Carlos Soto-Faguas, PhD, who received an APDA Post-doctoral Fellowship from 2024–2026 to investigate the role of the Christchurch APOE mutation in PD.
What Is the Christchurch Mutation?
The Christchurch mutation, first identified in New Zealand, is a rare variation of the APOE gene. It drew attention after it was identified in a woman in Colombia who had inherited a genetic mutation that put her at exceptionally high risk of developing Alzheimer’s disease at an early age. Despite that risk, she did not develop dementia until much later than expected.
Researchers discovered that she also carried the Christchurch variant of APOE, leading scientists to investigate whether this rare genetic variation helped protect her brain from the effects of Alzheimer’s disease.
Subsequent research suggested that the Christchurch variant may reduce the accumulation of certain proteins associated with Alzheimer’s disease, including tau. The OHSU researchers wanted to know whether the same mutation might also affect proteins involved in Parkinson’s disease.
What Did the Researchers Find?

The OHSU research team was led by Vivek Unni, MD, PhD, Associate Professor and Director of the Jungers Center for Neurosciences Research and the John Hammerstad, MD, Professor of Basic Research of Movement Disorders at OHSU. Dr. Unni is also a member of APDA’s Scientific Advisory Board.
The researchers developed genetically modified mice that carried the Christchurch mutation and studied how the mutation affected the buildup and spread of several proteins involved in neurodegenerative diseases.
One of their primary areas of focus was alpha-synuclein. In PD and dementia with Lewy bodies, alpha-synuclein can accumulate and clump together in the brain, forming structures known as Lewy bodies.
Importantly, the researchers found that mice carrying the Christchurch mutation had less formation and spread of abnormal alpha-synuclein aggregates in the brain.
Could This Lead to Gene Therapy?
One of the most interesting questions raised by this research is whether scientists could someday reproduce the protective effects of the Christchurch mutation in people who do not naturally carry it.
One possible approach is gene therapy, which involves delivering genetic material into cells to change or influence how those cells function.
Researchers are already exploring a similar strategy involving another version of APOE, called APOE2, which has also been associated with a reduced risk of Alzheimer’s disease.
Dr. Unni has suggested that the Christchurch mutation could potentially provide even greater protective effects than APOE2. His laboratory hopes to conduct additional preclinical studies to determine whether a Christchurch-based gene therapy could eventually be considered for human clinical trials.
There is still a great deal of research to be done before that could happen, and Dr. Unni estimates that such studies are likely still several years away.
What Does This Mean for People with Parkinson’s Disease?
The finding that the Christchurch mutation of APOE decreases the formation and spread of alpha-synuclein aggregates is very encouraging, but also very early. These results were found in mice which do not always translate to people.
Still, the study provides an exciting new direction for Parkinson’s research. By understanding how a naturally occurring genetic mutation can reduce the accumulation and spread of alpha-synuclein, scientists may identify new ways to interfere with the biological processes that contribute to PD. The APDA-funded research at OHSU represents an early but promising step toward that goal.
Please visit the Research section of our website to learn more about the exciting work that we fund. If you’d like to support PD research with a donation, it would be greatly appreciated.
